Výsledky vyhledávání - "Rosa I Gallagher"

Akademický článek

Clinical and immune responses to neoadjuvant fulvestrant with or without enzalutamide in ER+/Her2− breast cancer

Publikováno v: npj Breast Cancer, Vol 10, Iss 1, Pp 1-14 (2024)

Abstract Most ER+ breast cancers (BC) express androgen receptors (AR). This randomized phase II trial of 4 months of neoadjuvant fulvestrant (Fulv) alone or with enzalutamide (Combo) assessed whether adding AR blockade to Fulv would limit residual tu

Externí odkaz: https://doaj.org/article/564ac0eba47340f495698648097af1b7

Zobrazit plný text záznamu

Akademický článek

Malignant precursor cells pre-exist in human breast DCIS and require autophagy for survival.

Autor: Virginia Espina, Brian D Mariani, Rosa I Gallagher, Khoa Tran, Stacey Banks, Joy Wiedemann, Heather Huryk, Claudius Mueller, Luana Adamo, Jianghong Deng, Emanuel F Petricoin, Lucia Pastore, Syed Zaman, Geetha Menezes, James Mize, Jasbir Johal, Kirsten Edmiston, Lance A Liotta

Publikováno v: PLoS ONE, Vol 5, Iss 4, p e10240 (2010)

BACKGROUND: While it is accepted that a majority of invasive breast cancer progresses from a ductal carcinoma in situ (DCIS) precursor stage, very little is known about the factors that promote survival of DCIS neoplastic cells within the hypoxic, nu

Externí odkaz: https://doaj.org/article/fd689cee129b4338823f5f07411ce786

Zobrazit plný text záznamu

Akademický článek

Establishment and characterization of patient-derived xenograft of a rare pediatric anaplastic pleomorphic xanthoastrocytoma (PXA) bearing a CDC42SE2-BRAF fusion

Publikováno v: Scientific Reports, Vol 13, Iss 1, Pp 1-18 (2023)

Abstract Pleomorphic xanthoastrocytoma (PXA) is a rare subset of primary pediatric glioma with 70% 5-year disease free survival. However, up to 20% of cases present with local recurrence and malignant transformation into more aggressive type anaplast

Externí odkaz: https://doaj.org/article/e5789262b3ec42119349962b8c13096b

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Phase II trial of fulvestrant plus enzalutamide in ER+/HER2− advanced breast cancer

Publikováno v: npj Breast Cancer, Vol 9, Iss 1, Pp 1-10 (2023)

Abstract This clinical trial combined fulvestrant with the anti-androgen enzalutamide in women with metastatic ER+/HER2− breast cancer (BC). Eligible patients were women with ECOG 0–2, ER+/HER2− measurable or evaluable metastatic BC. Prior fulv

Externí odkaz: https://doaj.org/article/ad0c82b5d82a4e81a6170a0a923d1435

Zobrazit plný text záznamu

Abstract PD5-08: PD5-08 Drug target activation mapping of matched triple negative primary and axillary lymph node metastases identifies and links the ER-AR-GR steroid hormone receptor axis with downstream AKT activation

Autor: Julia Wulfkuhle, Page Blas, Heather Williams, Claudius Mueller, Rosa I. Gallagher, Mariaelena Pierobon, Joyce O’Shaughnessy, Emanuel F. Petricoin

Publikováno v: Cancer Research. 83:PD5-08

Title: Drug target activation mapping of matched triple negative primary and axillary LN metastases identifies and links the ER-AR-GR steroid hormone receptor axis with downstream AKT activation Background: Triple negative breast cancer (TNBC) is com

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7f2db7fc1c543130062820b35a2e7d07
https://doi.org/10.1158/1538-7445.sabcs22-pd5-08

Zobrazit plný text záznamu

Abstract P4-08-13: The Use of Reverse Phase Protein Arrays (RPPA), Principal Component Analysis (PCA), and CScape Pathway Mapping to Identify New Tumor Vulnerability and Actionable Targets in Human Malignant Triple-Negative Breast cancer cell lines

Autor: Andrew P. Howell, Julia Wulfkuhle, Rosa I. Gallagher, Emanuel F. Petricoin, Amy H. Tang

Publikováno v: Cancer Research. 83:P4-08

Breast cancer is the major leading cause of cancer-related fatalities nationally and globally. There will be 287,850 new breast cancer cases and 43,250 breast cancer related deaths in the United States in 2022. The relapsed, treatment-resistant, undr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ce29258ecec8f55cf2d82fa56a33192a
https://doi.org/10.1158/1538-7445.sabcs22-p4-08-13

Zobrazit plný text záznamu

Akademický článek

Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL

Autor: Kallesh D. Jayappa, Craig A. Portell, Vicki L. Gordon, Brian J. Capaldo, Stefan Bekiranov, Mark J. Axelrod, L. Kyle Brett, Julia D. Wulfkuhle, Rosa I. Gallagher, Emanuel F. Petricoin, Timothy P. Bender, Michael E. Williams, Michael J. Weber

Publikováno v: Blood Advances, Vol 1, Iss 14, Pp 933-946 (2017)

Abstract: De novo resistance and rapid recurrence often characterize responses of B-cell malignancies to ibrutinib (IBR), indicating a need to develop drug combinations that block compensatory survival signaling and give deeper, more durable response

Externí odkaz: https://doaj.org/article/8971b2c6746d4ca78045d1f18e8e94de

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání